Bedrijfsoverzicht
Prelude Therapeutics Incorporated is a clinical-stage precision oncology entity dedicated to the discovery and development of novel precision cancer medicines aimed at serving underserved patient populations. The company operates within the Healthcare sector, specifically functioning in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities rather than established commercial product sales. Prelude Therapeutics Incorporated maintains a market capitalization of $256.49M and employs 79 individuals to execute its strategic objectives. Its annual revenue stands at $12.14M, figures that indicate the company is currently in a pre-revenue or early commercialization phase typical of clinical-stage biotechs where valuation is driven more by pipeline potential than current cash flow generation.
Financiële gezondheid
The company reported a revenue of $12.14M over the trailing twelve months, while simultaneously posting a net income of $-99,498,000 and an EBITDA of $-101,555,000. The substantial gap between the positive revenue figure and the significantly negative net income reveals a cost structure dominated by high operating expenses, likely driven by research and development activities and general corporate overhead common in the biotechnology sector. Prelude Therapeutics Incorporated generated a free cash flow of $-23,872,250, indicating that the company is burning cash to fund its operations and pipeline advancement. Despite the negative cash flow, the firm holds $103.21M in cash and cash equivalents, which provides a substantial buffer against its current obligations. The company carries $17.79M in debt, resulting in a debt-to-equity ratio of 25.92, which suggests a balance sheet that relies heavily on equity financing rather than leverage, though the ratio itself is elevated relative to mature corporations. This financial profile is further contextualized by a current ratio of 1.99, indicating that the company possesses 1.99 times more current assets than current liabilities, pointing to adequate short-term liquidity to meet upcoming financial commitments. Furthermore, the return on equity stands at -99.5% and the return on assets is -40.7%, metrics that reveal management is currently generating negative returns on the capital invested, a characteristic state for early-stage biotechnology firms before a product reaches commercial maturity.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not available due to the lack of earnings, while the forward P/E is listed as -3.56, implying that future earnings expectations are still negative and the traditional price-to-earnings metric is not applicable for valuation. The price-to-book ratio is 4.90, indicating that the market values the company at nearly five times its book value, a significant premium often found in biotechnology firms where intangible assets and intellectual property are not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 21.13 and an EV/EBITDA of -2.48, suggesting the market is pricing the stock based on revenue multiples rather than profitability, which is standard for companies in the growth phase of the product lifecycle. The stock has exhibited significant volatility, trading within a 52-week range bounded by a high of $4.82 and a low of $0.66. Without the current share price explicitly provided in the source data to calculate the exact percentage deviation, the trading range demonstrates a wide fluctuation typical of small-cap biotechnology stocks reacting to clinical trial data and market sentiment. The beta value is 0.71, which indicates that the stock's price volatility is lower than the broader market, suggesting it is less sensitive to general market movements compared to large-cap equities.
Growth & Income
Prelude Therapeutics Incorporated has achieved a revenue growth rate of 41.0% year-over-year, whereas earnings growth is not applicable due to the company's consistent net losses. The disparity between the robust revenue expansion and the non-existent earnings growth implies that the company is prioritizing top-line expansion and clinical progress over immediate profitability, a strategy common in the development of novel therapies. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any available earnings are theoretically reinvested into growth initiatives or preserved as cash reserves rather than distributed to shareholders. This reinvestment strategy aligns with the company's stage of development, where capital allocation focuses on advancing the JAK2V617F product for the treatment of myeloproliferative neoplasms and myelofibrosis. Overall, the growth and income profile reflects a capital-intensive growth model reliant on external funding or cash reserves to sustain operations until commercial milestones are reached.